11:30 am–12:30 pm Saturday, September 7

Beyond the Cure: The Children’s Oncology Group Uses Evidence and Clinical Trials to Study Late Effects in Childhood Cancer Survivors (C229)

coglogoChildhood cancer survivors are living longer than ever before, with overall survival rates exceeding 80%. As a result, survivors are living with chronic late health effects related to their curative treatments. Late effects may include second malignancies, endocrinopathies, cardiomyopathy, infertility, pulmonary function deficits, renal/ocular/auditory disorders, neurocognitive deficits, and metabolic syndrome.

Read more...
Speaker:
Eleanor Hendershot, MN BScN RN(EC)
CNE Hours
1
RX Hours
0.17
5:00–6:00 pm Thursday, September 5

Infant ALL: Rearranged for the Big Screen! Providing Care on COG AALL15P1, Nurses in a Leading Role! (C211)

coglogoAcute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, with 5-year overall survival rates exceeding 90% (Hunger, Lu, Devidas, Camitta, Gaynon, Winick, 2012). Unfortunately, infants with ALL are an exception to the improving survival trends and remain one of the most challenging populations in pediatric hematology/oncology (Kotecha, Gottardo, Kees, Cole, 2014).

Read more...
3:45–4:45 pm Thursday, September 5

Navigating 131I-MIBG and CAR T 19, in COG trials ANBL1531 and AALL1721: Sharing Care and Strategies for Success (C205)

coglogoThe Children’s Oncology Group (COG) is committed to improving outcomes for pediatric oncology patients with the high-risk disease through clinical trials. Despite tremendous advancements in pediatric oncology treatment, survival in two patient populations remains inferior. Patients with high-risk neuroblastoma have a projected 3-year event-free survival of 73% (Park et al., 2016), and patients with precursor B lineage acute lymphoblastic leukemia with positive minimal residual disease at the end of consolidation have a projected 5-year disease-free survival of 39% (Borowitz et al., 2015).

Read more...
2:15–3:15 pm Saturday, September 7

HCT & Gene Therapy in the Treatment of Inherited Metabolic Disorders (231)

Inherited metabolic disorders (IMDs) are a diverse group of diseases caused by genetic mutations that result in potentially lethal enzymatic abnormalities. Some IMDs such as adrenoleukodystrophy and mucopolysaccharidosis can be diagnosed by routine newborn screen, while others will present later in life when symptoms appear.

Read more...
Speaker:
Victoria Szenes, MS RN CPNP
CNE Hours
1
4:15–5:15 pm Friday, September 6

Immune-Mediated Thrombocytopenia: An Overview (221)

Immune-mediated thrombocytopenia, or “ITP,” is one of the most common causes of symptomatic thrombocytopenia in children and adolescents. Clinical presentation and course, epidemiology, diagnostic modalities and criteria, treatment options, and long-term sequelae will be reviewed with attention to the nurse/advanced practice nurse who desires a comprehensive overview of the subject. Case studies will be utilized to highlight the frequent clinical variance of the condition. Read more...
4:15–5:15 pm Friday, September 6

Advances in Pediatric Neuro-Oncology in the Molecular Era (218)

Pediatric CNS tumors as a group represent the most common solid tumor in childhood and encompass a wide variety of diagnoses, from benign to malignant. Recent advances in molecular profiling have led to significant changes in the classification of pediatric CNS tumors, with a positive impact on diagnosis, prognosis, and treatment. Gliomas have undergone reclassification with emphasis on molecular profile over histology, leading to a redefinition of traditional low-grade versus high-grade glioma.

Read more...
Speaker:
Cheryl Fischer, MSN RN CPNP
CNE Hours
1
11:30 am–12:30 pm Friday, September 6

High Dollar Medications and Therapies: Challenges for our Families and Challenges for Us! (215)

Treatment options for children with cancer continue to grow and bring exciting opportunities for a cure in situations where there was previously no hope. Some therapies come at a very high cost. At the same time, the cost of health care in the United States continues to grow. The complexity of healthcare reimbursement includes varied payment options, including governmental programs; commercial insurance, which can range from excellent coverage to a high deductible plan; and sometimes nontraditional methods of payment, such as shared ministry programs or “self-pay.”

Read more...
Speaker:
Kaye Schmidt, MA RN NEA-BC CPHON®
CNE Hours
1
11:30 am–12:30 pm Friday, September 6

Foundations of Pediatric Neuro-Oncology (214)

Pediatric central nervous system (CNS) tumors are a diverse group of tumors that together represent the most common solid tumor in children, with approximately 4,300 new cases diagnosed in the US each year. Management of children with CNS tumors requires knowledge of the unique aspects of care associated with this particular patient population beyond general oncology care.

Read more...
Speaker:
Cheryl Fischer, MSN RN CPNP
CNE Hours
1
11:30 am–12:30 pm Friday, September 6

The Forgotten Organ- Nephrotoxicity and other Kidney Disorders in Childhood Cancer (213)

Development of kidney disease is a significant occurrence among children and adolescent patients treated for cancer and require prompt attention, intervention, and follow-up. Renal disease in the pediatric cancer setting is often an underdiagnosed condition, partly due to the emphasis and priority of achieving a cure. Renal disease in the young patient with cancer may result from the malignant process itself or from adverse effects from treatment, including chemotherapy, radiation therapy, surgery, or supportive therapy.

Read more...
5:00–6:00 pm Thursday, September 5

Non-Pharmacologic Treatment of Pain in Sickle Cell Disease (207)

Sickle cell disease (SCD) is characterized by episodes of severe and unpredictable pain that requires adaptation to remain healthy and functional. A more holistic view of pain assessment and treatment is necessary to address the bio-psychosocial needs of the individual in or at risk for pain. The treatment of SCD should include all available modalities to enhance the disease process, pain management, and psychosocial functioning.

Read more...
Speaker:
Megan Coco, MSN RN CPNP-PC
CNE Hours
1
Subscribe to this RSS feed